Compare Repligen Corporation Common Stock (RGEN) vs SentinelOne Inc. Class A Common Stock (S) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs SentinelOne Inc. Class A Common Stock — how do they compare? Repligen Corporation Common Stock trades at $178.18 (market cap $11.14B), while SentinelOne Inc. Class A Common Stock trades at $22.64 (market cap $8.36B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and SentinelOne Inc. Class A Common Stock is more actively traded (27,558,313 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and SentinelOne Inc. Class A Common Stock for 6 Days on average.
| RGEN | S | |
|---|---|---|
Market Cap | $11.14B | $8.36B |
Volume | 1,259,263 | 27,558,313 |
Sector | Health | Technology |
52-Week High | $194.57 | $26.27 |
52-Week Low | $102.87 | $11.94 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.02B | $7.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SentinelOne (S) trades at $24.01, down 6.43% amid news of a $1.25 billion convertible notes offering. The stock shows bullish technical signals with strong moving average support, though oscillators remain neutral. Fundamentally, the company maintains robust revenue growth (21% YoY) and high gross margins (72.54%) but continues to report significant net losses (-$288M in 2025). Recent analyst recognition as a leader in endpoint security and expanding cloud capabilities provide positive business momentum.
Investment outlook balances strong growth potential against persistent profitability challenges. The convertible notes offering signals aggressive expansion but increases financial leverage. With 65% analyst buy ratings and a $23.42 consensus target, Wall Street remains optimistic about long-term cybersecurity demand, though investors face execution risk and competitive pressures in a capital-intensive growth phase.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About SentinelOne Inc. Class A Common Stock
SentinelOne provides an AI-powered cybersecurity platform for organizations. Its Singularity platform helps detect, prevent, and respond to threats across endpoints, cloud workloads, identities, and connected devices.
Read more on S →
